Dry AMD Symposium 1

Related

• 

  Safety and Efficacy of SC Elamipretide to Treat Noncentral Geographic Atrophy: ReCLAIM-1 Results and Phase II ReCLAIM-2 Baseline Characteristics

  David R Lally, MD

  Annual Meeting Talks

  2021

• 

  Surveying the Dry AMD Landscape. Is help on the way?

  David S. Boyer, MD

  Updates from the Field

  2019

• 

  Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

  Jared S. Nielsen, MD, MBA

  Updates from the Field

  2022